Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1397)	7/30/2015 9:53:39 AM
From: eico20	Respond to of 2026

good point on Rayva PR, let's see what they have to say in the conf call, everything is delayed with these guys

To: phoenix_rising who wrote (1397)	7/30/2015 12:00:53 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

Any release of top line results for RayVa would be in a separate press release. If released before the CC then they could further discuss it during the CC. If they said something different in the press release today, they would have been obliged to release the results today. So we wait, which is always the case for us retail investors, even the ones with Singapore-sized portfolios. ; )

To: phoenix_rising who wrote (1397)	8/4/2015 6:10:49 PM
From: mokelumne river	Read Replies (2) \| Respond to of 2026

Just to put a fine point on the 6/15 announcement that RayVa enrollment was completed, that did not mean that the last patient had been treated. I had to reread the PR to understand that. Actual treatment of that last patient may have been weeks later. So I am not expecting RayVa Phase 2a results to be announced tomorrow at the conference call. Pascoe may say that the last patient was treated and the blinded data is now being analyzed by whoever does the analysis. Or maybe he will just reiterate that the results will be out in this the third quarter. I think RayVa has little if any market recognition. Hope that changes with good results and an FDA green light on the Phase 2b.